Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07501208Phase 1Withdrawn

Dendritic Cell Vaccine to Prevent COVID-19

Role: collaborator

NCT04690387Phase 1Completed

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection

Role: collaborator

NCT05007496Phase 2Completed

Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19

Role: collaborator

NCT04685603Phase 1Unknown

Dendritic Cell Vaccine to Prevent COVID-19

Role: collaborator

All 4 trials loaded